Evidence map›Paper›PMID 40582892›Full record

ArticleMicrobiology and immunology2025

Bifidobacterium bifidum G9-1 Survives in the Intestinal Environment and Influences the Gut Microbiota Despite the Presence of Antimicrobials.

Haruka Yokota, Yutaka Makizaki, Yoshiki Tanaka, Hiroshi Ohno

Erratum issuedAbstract read
In one paragraph

Article in Microbiology and immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Haruka YokotaBiofermin Pharmaceutical Co. Ltd., Kobe, Japan.ORCID https://orcid.org/0009-0009-3709-426X
Yutaka MakizakiBiofermin Pharmaceutical Co. Ltd., Kobe, Japan.ORCID https://orcid.org/0000-0001-7971-7503
Yoshiki TanakaBiofermin Pharmaceutical Co. Ltd., Kobe, Japan.ORCID https://orcid.org/0000-0003-0050-587X
Hiroshi OhnoBiofermin Pharmaceutical Co. Ltd., Kobe, Japan.

Funding

The authors received no specific funding for this work.
6 · The paper itself

Abstract

Probiotics can help prevent antibiotic-associated diarrhea; however, those lacking antimicrobial resistance may be ineffective during antimicrobial treatment. Here, we aimed to examine the effects of antimicrobials on the probiotic strain Bifidobacterium bifidum G9-1 (BBG9-1). Minimum inhibitory concentrations were determined in vitro by culturing B. bifidum G9-1 with antimicrobials and assessing its viability. For in vivo analysis, germ-free and specific pathogen-free mice were administered B. bifidum G9-1 along with antimicrobials. Gut microbiota composition and viable B. bifidum G9-1 abundance were determined. Bifidobacterium bifidum G9-1 was highly sensitive to antimicrobials in vitro. However, in a complex bacterial environment mimicking the gut environment, the abundance of viable B. bifidum G9-1 was significantly high despite antimicrobial exposure. Dominant bacterial populations were more affected by antimicrobials than nondominant populations, with B. bifidum G9-1 exhibiting increased viability in the presence of diverse bacterial species. In vivo, combined administration of antimicrobials and B. bifidum G9-1 significantly reduced B. bifidum G9-1 abundance in germ-free mice but not in specific pathogen-free mice, where the gut microbiota composition shifted following administration of B. bifidum G9-1. The presence of diverse live bacteria in the intestine promotes the survival of B. bifidum G9-1 and its beneficial effects, even in the presence of antimicrobials. This finding suggests that B. bifidum G9-1, despite lacking intrinsic antimicrobial resistance, can survive and reach the large intestine, maintaining its probiotic function. Therefore, B. bifidum G9-1 can potentially be used for antibiotic-associated diarrhea prevention.

Indexed as

Anti-Bacterial AgentsAnti-Infective AgentsBifidobacterium bifidumGastrointestinal MicrobiomeIntestinesProbioticsAnimalsDiarrheaFecesGerm-Free LifeMiceMicrobial Sensitivity TestsMicrobial ViabilitySpecific Pathogen-Free OrganismsAnti-Bacterial AgentsAnti-Infective AgentsantimicrobialBifidobacterium bifidum G9‐1 (BBG9‐1)intestinal microbiotaminimum inhibitory concentrationprobiotic

Identifiers

PMID40582892
PMCPMC12414442

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.